Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CanSino Biologics, Inc. Class H ( (HK:6185) ) just unveiled an update.
CanSino Biologics Inc. has announced its 2025 second extraordinary general meeting, where significant amendments to corporate governance policies and the company’s Articles of Association will be discussed. The meeting will also address the appointment of new independent non-executive directors and the utilization of reserves to offset losses, indicating a strategic move to strengthen its governance framework and financial stability.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, focusing on the development and production of vaccines. It operates in the pharmaceutical industry, primarily targeting infectious diseases with innovative vaccine solutions.
Average Trading Volume: 1,504,905
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.36B
Find detailed analytics on 6185 stock on TipRanks’ Stock Analysis page.